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Abstract A distinguishing feature of serpins is their ability to
undergo a conformational change consisting in insertion of the
reactive centre loop (RCL) into L-sheet A. In the serpin
plasminogen activator inhibitor-1 (PAI-1), RCL movements are
regulated by vitronectin, having a previously poorly defined
binding site lateral to PAI-1’s L-sheet A. Using a novel strategy,
based on identification of amino acid residues necessary for
vitronectin protection of PAI-1 against inactivation by 4,4P-
dianilino-1,1P-bisnaphthyl-5,5P-disulfonic acid, we have defined a
vitronectin binding surface spanning 10 residues between K-helix
F, L-strand 2A, and K-helix E. Our results contribute to
elucidating the unique serpin conformational change. - 2002
Published by Elsevier Science B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
The serpins constitute a protein family of which the best
characterised members, including plasminogen activator in-
hibitor-1 (PAI-1), are inhibitors of mammalian serine protein-
ases. Decisive for the inhibitory mechanism of serpins is the
surface-exposed, approximately 20 amino acids long reactive
centre loop (the RCL) (see Fig. 1). The reaction between
serpin and proteinase is initiated by formation of a docking
complex in which the P1^P1P bond in the RCL interacts non-
covalently with the active site of the proteinase. In the ensuing
locking step, the P1^P1P bond is cleaved, the P1 residue
coupled to the active site serine of the proteinase by an ester
bond, the N-terminal part of the RCL inserted as strand 4 in
L-sheet A (s4A), and the proteinase translocated to the oppo-
site pole of the molecule. The proteinase is thereby distorted
and the completion of the catalytic cycle halted. The energy
needed for proteinase distortion stems from stabilisation of
the serpin in the ‘relaxed’ conformation by insertion of the
RCL into L-sheet A, as compared to the ‘stressed’, unstable
active conformation with a surface-exposed RCL. At some
conditions, proteinase distortion cannot keep pace with ester
bond hydrolysis, resulting in abortive complex formation, full
cleavage of the P1^P1P bond, insertion of the RCL into L-sheet
A and release of an active proteinase. Serpins following this
alternative path are said to exhibit substrate behaviour (for
reviews, see [1^3]).
RCL insertion is coupled to conformational changes in oth-
er parts of the molecule, including the £exible joint region
around K-helix D (hD) and hE [4] (see Fig. 1). A few organo-
chemical compounds able to neutralise PAI-1 activity bind to
the £exible joint region, including bis-ANS (4,4P-dianilino-
1,1P-bisnaphthyl-5,5P-disulfonic acid), which inactivate PAI-1
by inducing substrate behaviour followed by polymerisation
[5^6].
PAI-1 possesses two unique features not shared with other
serpins. First, it spontaneous assumes an inactive, relaxed, so-
called latent state in which the intact RCL is inserted into
L-sheet A [8]. Second, stressed, but not relaxed PAI-1, binds
the N-terminal 44 amino acids long somatomedin B domain
of the Mr 70 000 protein vitronectin (VN), which thereby de-
lays the latency transition of PAI-1 (for a review, see [3]) and
protects it from bis-ANS-induced substrate behaviour and
polymerisation [6^7]. VN causes a conformational change of
the RCL [9^10]. VN binds to the £exible joint region of PAI-
1, as suggested by four lines of evidence. By screening PAI-1
variants produced by random mutagenesis, the substitutions
L118P and Q125K were found to result in a signi¢cantly
reduced VN binding [11]. A recent report implicated residues
116^120 in VN binding and con¢rmed the reduced VN a⁄nity
of PAI-1 Q125K [12]. Investigations with the less accurate
methods of antibody competition [13] and PAI-1-PAI-2 chi-
meras [14] also gave results compatible with VN binding to
the £exible joint region. Thus, there seems to be a bidirec-
tional communication between the VN binding area in the
£exible joint region and the RCL.
However, the exact architecture of the VN binding site, i.e.,
the identity of the PAI-1 residues at the PAI-1^VN interphase,
has remained elusive. We have now employed site-directed
mutagenesis and the competitive e¡ects of VN and bis-ANS
for obtaining a map of the VN binding area.
2. Materials and methods
2.1. Materials
The cDNAs for wild-type (wt) and substituted human PAI-1, ex-
tended at the N-terminus with a hexa-His tag and a recognition motif
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for heart muscle kinase, were produced by standard methods in the
Escherichia coli expression vector pT7-PL [15]. Transformed E. coli
BL21(DE3)pLysS cells from 1 l cultures, treated with 0.5 mM isopro-
pyl thio-L-D-galactoside to induce PAI-1 expression, were harvested
by centrifugation (7000Ug, 20 min), re-suspended in 35 ml phosphate-
bu¡ered saline (137 mM NaCl, 2.7 mM KCl, 1.4 mM KH2PO4, 4.3
mM Na2HPO4), and disrupted by sonication. The homogenates were
centrifuged (10 000Ug, 30 min), ¢ltered (0.22 Wm), supplemented with
2 M NaCl, 10 mM imidazole and 5% glycerol, and applied to a 5 ml
Ni-NTA column equilibrated in the same bu¡er. PAI-1 was eluted
with 200 mM imidazole. The eluted protein was subjected to gel
¢ltration on a Superdex 75 column (1.6U60 cm) equilibrated in
HEPES-bu¡ered saline (10 mM HEPES, 140 mM NaCl, pH 7.4)
supplemented with 5% glycerol and 1 M NaCl. The procedure rou-
tinely gave 10^15 mg PAI-1/l bacterial culture. The preparations con-
tained PAI-1 which was more than 95% pure as evaluated by SDS^
PAGE and Coomassie blue staining. N-terminal sequencing showed
the expected N-terminus, i.e., (M)GSMGSHHHHHHGSRRASV-
HHT, only missing the initiating M, indicated in parentheses. The
N-terminal extension did not a¡ect PAI-1’s speci¢c inhibitory activity,
its second order rate constant for reaction with urokinase-type plas-
minogen activator (uPA), its VN binding, or its rate of latency tran-
sition.
The PAI-1 amino acid numbering system used was that described
earlier, based on the determination of the N-terminal amino acid se-
quence of the protein as S1-A2-V3-H4-H5T [16].
Bis-ANS was from Molecular Probes, Eugene, OR, USA. S-2444
(pyro-Glu-Gly-Arg-p-nitroanilide) was from Chromogenix, Mo«lndal,
Sweden. Human uPA was from Wakamoto Pharmacautical Co., To-
kyo, Japan. Human multimeric VN was from BD Biosciences, Frank-
lin Lakes, NJ, USA.
2.2. Measurement of the speci¢c inhibitory activity of PAI-1
To measure the e¡ects of VN and bis-ANS on the speci¢c inhib-
itory activity of wt and substituted PAI-1, i.e., the fraction of inhib-
itor forming a stable complex with uPA, PAI-1 was preincubated for
10 min on ice at concentrations of 10^30 Wg/ml, in the absence or
presence of a 1.5-fold molar excess of VN. It was then serially diluted
at 37‡C with HEPES-bu¡ered saline supplemented with 0.25% gelatin,
resulting in PAI-1 concentrations between 0.02 and 40 Wg/ml in a
volume of 100 Wl. 50 Wl aliquots of bis-ANS solution were added,
the bis-ANS concentration varying between dilution series. The mix-
tures were incubated for 10 min. 50 Wl aliquots with 1 Wg/ml uPA were
added. Incubation was continued for at least 2 min, su⁄cient for the
process of inhibition of uPA to come to an end. The remaining uPA
enzyme activity was determined by incubation with the substrate S-
2444 and measurement of the increase in absorbance at 405 nm. The
speci¢c inhibitory activity of PAI-1 was calculated from the amount
of PAI-1 that had to be added to inhibit 50% of the uPA. The IC50
values for bis-ANS neutralisation of PAI-1 were determined as the
bis-ANS concentrations causing a 50% reduction in the PAI-1 speci¢c
inhibitory activity.
3. Results
Among about 40 A-substituted variants of PAI-1, produced
to localise its VN-binding area, a substantial fraction had a
reduced inhibitory activity, because of either an increased
tendency to substrate behaviour or an increased fraction of
PAI-1 being in an inert, probably latent state (data not
shown). It was thus clear that the results of a direct VN^
PAI-1 binding analysis would be misleading, as any relaxed
form of PAI-1 does not bind to VN.
We therefore chose an alternative approach, intending to
measure the interaction of VN with only the fraction of active
Fig. 1. The three-dimensional structure of active PAI-1 [20] and residues important for VN protection of PAI-1 against bis-ANS. A: Ribbon
diagram. Some important secondary structural elements are indicated. B: Surface diagram, in the same orientation as in A. Substitution of the
red residues resulted in an IC50 for bis-ANS inactivation of PAI-1 in the presence of VN below 6 WM. Substitution of the yellow residues re-
sulted in an IC50 for bis-ANS inactivation of PAI-1 in the presence of VN between 10 and 20 WM. Substitution of the cyan residues did not re-
sult in signi¢cant changes of the IC50 for bis-ANS inactivation of PAI-1 in the presence of VN. K325 is not visible with the orientation used.
N169 is not visible because it is buried in the structure. The ¢gures were prepared with SWISSPDBVIEWER v3.7b2 (http://www.expasy.ch).
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PAI-1 in the preparations. The IC50 value for the bis-ANS-
induced reduction of the speci¢c inhibitory activity of PAI-1 is
50^100-fold higher for the PAI-1-VN complex than for PAI-1
alone [6^7]. Any PAI-1 variant with a defect in VN binding
would therefore be expected to be less e⁄ciently protected
against bis-ANS by VN. The strategy chosen was therefore
to measure the IC50 value for bis-ANS reduction of the spe-
ci¢c inhibitory activity of PAI-1 variants in the absence and
presence of VN.
In the absence of VN, the IC50 values for bis-ANS neutral-
isation were invariably around 0.7 WM (Table 1). In the pres-
ence of VN, wt and most variants had an IC50 value about 50
WM. Strikingly, however, the variants F100A, R103A, L107A,
M112A, T122A, Q125A, Q125K, I137A, N139A, W141A,
and N169A had an IC50 value below 6 WM in the presence
of VN. In addition, the variants K124, E132A, D140A,
M149A, N152A, R164A, and K325A had an IC50 value be-
tween 10 and 20 WM in the presence of VN.
4. Discussion
The ‘protection against bis-ANS’ assay used here has the
advantage of measuring the interaction of VN with only the
active PAI-1 in the preparations, without the risk of misinter-
pretations of the results due to a fraction of inactive, possibly
latent PAI-1. VN protection against bis-ANS may be due to
direct steric competition between VN and bis-ANS or to a
VN-induced conformational change of the bis-ANS-binding
area. Using charge reversal mutations, we previously impli-
cated the region around R78, R117, and R120 in the binding
of bis-ANS [6], suggesting a partial overlap between the VN
and bis-ANS binding areas. Besides the binding a⁄nity, IC50-
values are also sensitive to the rate by which the bis-ANS-
induced, inactivation-associated conformational change
spreads through PAI-1. Therefore, the protective e¡ect of
VN against bis-ANS may also depend on a slower bis-ANS-
induced conformational change of the PAI-1-VN-complex
than of free PAI-1. Generally, observation of a substitution
having a di¡erent e¡ect on the IC50 value for bis-ANS neu-
tralisation of PAI-1 in the absence and presence of VN shows
that the corresponding amino acid side chain is in di¡erent
surroundings in PAI-1 in the absence and presence of VN.
In our analysis, we relied almost totally on A-substitutions
(except for the Q125K substitution), of single, mostly surface-
exposed residues. By avoiding charge reversal mutations, we
circumvented the uncertainties related to the use of mutants
with a changed bis-ANS a⁄nity and were for instance able to
analyse the importance of R120, although an R120E substi-
tution leads to a reduced bis-ANS susceptibility ([6] and data
not shown). Our conclusions of a lack of importance for VN
binding of F116 and R120 is not in con£ict with the report of
a reduced VN a⁄nity of the substituent F116A-K117A-
L118A-F119A-R120A [12], as this extensive substitution, in-
cluding that of the buried F119, may have perturbed the
structure in a manner also involving the residues we have
implicated in binding.
Among the residues implicated in VN^PAI-1 interactions
here, F100, R103, L107, M112, T122, K124, Q125, I137,
D140, and W141 are surface-exposed and localised in a re-
stricted area between s2A, hE, and hF (Fig. 1). We propose
that they form the surface of PAI-1 which binds the somato-
medin B domain of VN. The present implication of Q125 in
VN binding is in full agreement with the original conclusion
by Lawrence et al. [11], reporting a reduced binding of PAI-1
Q125K. The fact that Q125 scores as necessary for VN pro-
tection against bis-ANS here, both when using a K and an A
substitution, lends credibility to the present experimental
strategy. According to the available three-dimensional struc-
tures of PAI-1 [8,17^20], the architecture of this region
changes dramatically upon the stressed-to-relaxed transition
due to the translocation of s1A and s2A, in agreement with
relaxed PAI-1 having a much lower VN a⁄nity than stressed
PAI-1.
E132, N139, M149, N152, N169, R164, and K325, also
implicated in VN^PAI-1 interactions here, are scattered out-
side the surface de¢ned by the other residues (Fig. 1) and
Table 1
IC50 for neutralisation of PAI-1 by bis-ANS in the absence and the presence of VN
PAI-1 variant Secondary structural element IC50 without VN (WM) IC50 with VN (WM)
wt 0.73U 0.06 (3) 51U 18 (6)
F100A s2A 0.75U 0.05 (3) 2.7 U 0.3 (3)
R103A s2A^hE loop 0.63U 0.15 (3) 4.9 U 2.5 (3)
L107A s2A^hE loop 0.66U 0.13 (3) 5.6 U 3.2 (3)
M112A hE 0.73U 0.23 (3) 5.3 U 1.7 (3)
T122A s1A 0.60U 0.00 (3) 4.6 U 2.4 (3)
K124A s1A 0.71U 0.26 (3) 15U 2 (3)
Q125A s1A 0.65U 0.11 (4) 4.4 U 3.8 (3)
Q125K s1A 0.68U 0.11 (3) 2.4 U 1.0 (3)
E132A hF 0.70U 0.20 (3) 12U 6 (6)
I137A hF 0.67U 0.04 (3) 3.4 U 1.4 (3)
N139A hF 0.82U 0.10 (3) 4.6 U 1.8 (3)
D140A hF 0.66U 0.27 (3) 12U 4 (3)
W141 hF 0.71U 0.24 (3) 2.9 U 0.5 (3)
M149A hF^s3A loop 0.68U 0.04 (3) 13U 4 (3)
N152A hF^s3A loop 0.67U 0.03 (3) 16U 3 (3)
R164A s3A 0.65U 0.19 (3) 11U 4 (3)
K325A s5A 0.60U 0.10 (3) 17U 1 (3)
N169A s3A 0.55U 0.01 (3) 4.6 U 1.9 (3)
The table shows means, standard deviations, and numbers of determinations. The following substituents did not di¡er from wt with respect to
the IC50 values for bis-ANS neutralisation of PAI-1 in the absence or presence of VN: Q102A, D104A, K106A, Q109A, P113A, F116A,
R120A, D127A, E130A, R133A, R135A, F136A, T144A, H145A, D160A, E283A, E315A.
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therefore unlikely to be implicated directly in VN binding.
Instead, these residues may be important for maintaining
the proper architecture of the binding area or may reorient
themselves upon VN binding and thereby confer a signal from
the VN binding area to the RCL. In fact, most of these res-
idues are localised at interfaces between secondary structural
elements assumed to move relative to each other during RCL
insertion (for a review, see [3]). An abnormal response to VN
of the latency transition rate of K325A suggested that PAI-1
K325 plays an important role in conferring a signal from VN
binding to the RCL [7,21].
Taken together, our observations suggest that VN binds in
an area bordered by s2A, hE, and hF. By communication
through hF, the hF^s3A loop, s3A, and s5A, this leads to
conformational changes of the RCL. These changes in turn
stabilise PAI-1 against latency transition, substrate behaviour,
and polymerisation. More precise physico-chemical methods
can now be used to de¢ne the exact role of each individual
residue.
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